Skip to content
    MTD
    Earnings call· Mar 2026(Q1 FY26)

    METTLER TOLEDO INTERNATIONAL INC/ Q1 FY26 earnings call MTD

    May 8, 2026 Source

    Executive summary

    Mettler-Toledo Q1 FY26 — Strong EPS Growth Amidst Market Uncertainty

    Mettler-Toledo delivered solid Q1 FY26 results, with strong adjusted EPS growth driven by margin initiatives and innovation, despite an increasingly uncertain market environment. The company reiterated its full-year sales guidance while raising its adjusted EPS outlook, reflecting confidence in second-half growth and productivity programs. Management highlighted investments in automation, digitalization, and onshoring as future growth drivers, alongside strong performance in China and bioprocessing.

    Highlights

    5
    • Adjusted EPS grew 9% year-over-year to $8.91, exceeding expectations.

    • Local currency sales increased 3%, with 1% growth excluding acquisitions, demonstrating resilience.

    • Service revenue grew 7% (5% excluding acquisitions), highlighting strong customer connection and recurring revenue.

    • China sales grew 4% in local currency, driven by Industrial business momentum, with full-year expectations raised to mid-single digits.

    • Product Inspection sales grew 5% (6% excluding acquisitions), benefiting from innovation and mid-market strategy.

    Concerns

    5
    • Gross margin decreased 80 basis points to 58.7% due to unfavorable foreign currency and acquisitions, and a 90 basis point tariff headwind.

    • Adjusted operating margin decreased 80 basis points to 26%, with tariffs reducing operating profit by 4%.

    • Laboratory sales were flat excluding acquisitions, impacted by soft demand from academia and biotech customers for pipettes, and delayed customer investments in Europe.

    • Core Industrial sales were flat excluding acquisitions, reflecting cautious purchasing patterns and customer delays due to geopolitical and macro uncertainty.

    • Free cash flow of $120 million was negatively impacted by $58 million higher tax payments compared to the prior year.

    Guidance & targets

    22
    CategoryTargetConfidence
    Full-year 2026 Local Currency Sales Growth
    approximately 4%
    high materiality
    High
    Full-year 2026 Acquisition Contribution to Sales Growth
    approximate 1.5% in the first half of the year and less than 8% for the full year
    medium materiality
    High
    Full-year 2026 Adjusted EPS
    $46.30 to $46.95
    high materiality
    High
    Full-year 2026 FX Impact on Sales Growth
    2% benefit
    medium materiality
    High
    Full-year 2026 FX Impact on EPS
    neutral
    medium materiality
    High
    Q2 2026 Local Currency Sales Growth
    approximately 3%
    high materiality
    High
    Q2 2026 Adjusted EPS
    $10.70 to $10.85
    high materiality
    High
    Q2 2026 FX Impact on Sales
    approximately 2% benefit
    medium materiality
    High
    Q2 2026 FX Impact on Adjusted EPS
    neutral
    medium materiality
    High
    Full-year 2026 Total Amortization
    approximately $78 million
    low materiality
    High
    Full-year 2026 Purchased Intangible Amortization (pretax)
    approximately $28 million
    low materiality
    High
    Full-year 2026 Interest Expense
    approximately $70 million
    low materiality
    High
    Full-year 2026 Other Income
    approximately $25 million
    low materiality
    High
    Full-year 2026 Tax Rate (before discrete items)
    19%
    medium materiality
    High
    Full-year 2026 Free Cash Flow
    approximately $900 million
    high materiality
    High
    Full-year 2026 Share Repurchases
    $825 million to $875 million
    high materiality
    High
    Full-year 2026 China Growth Expectations
    mid-single digit
    medium materiality
    High
    Full-year 2026 Lab Sales Growth
    low to mid-single digit
    medium materiality
    Medium
    Full-year 2026 Core Industrial Sales Growth
    low to mid-single digit
    medium materiality
    Medium
    Full-year 2026 Product Inspection Sales Growth
    mid-single digit
    medium materiality
    Medium
    Full-year 2026 Americas Sales Growth
    low single digit
    medium materiality
    Medium
    Full-year 2026 Europe Sales Growth
    low single digit
    medium materiality
    Medium

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Laboratory
    Modest growth across most product categories, strong growth in bioprocessing, partially offset by decline in pipettes due to soft demand from academia and biotech. Expect gradual increase in activity in H2 FY26.
    Local currency sales ex-acquisitions: flatBioprocessing growth: strongPipettes growth: negative
    flat
    Industrial
    Overall strong growth, with Product Inspection benefiting from innovation and mid-market strategy. Core Industrial saw cautious purchasing patterns across most end markets. Industrial automation solutions are gaining momentum, especially in China.
    Local currency sales: +5%Local currency sales ex-acquisitions: +2%Core Industrial growth ex-acquisitions: flatProduct Inspection growth: +5%Product Inspection growth ex-acquisitions: +6%
    +5%
    Food Retail
    Strong sales growth against easy year comparisons. Business is lumpy, with strong growth in Europe offsetting declines in the U.S. in Q1.
    +7%
    Americas
    Growth in Lab and Product Inspection, but Core Industrial sales were soft due to customer delays and market uncertainty. Optimistic for growth in H2 FY26.
    Local currency sales ex-acquisitions: flatLab business growth: included strong bioprocessing growthProduct Inspection growth: strongCore Industrial sales: soft
    +2%
    Europe
    Strong growth in Product Inspection and Food Retail offset by softer market conditions, especially in the chemical sector due to higher energy costs.
    +1%
    Asia/Rest of World
    Good overall growth, with China showing strong momentum led by the Industrial business. Very good growth also seen in India, Southeast Asia, and other emerging markets.
    Local currency sales ex-acquisitions: +3%China growth: +4%Industrial business in China: led growthIndia growth: very goodSoutheast Asia growth: very good
    +5%

    Operational metrics

    17
    Gross margin
    58.7%-80 bps YoY
    Q1 FY26

    Gross margin decreased due to unfavorable foreign currency and acquisitions, but improved excluding these factors. Incremental tariffs were a significant headwind.

    Adjusted operating profit
    $246 million+4% YoY
    Q1 FY26

    Adjusted operating profit increased year-over-year.

    Adjusted operating margin
    26%-80 bps YoY
    Q1 FY26

    Adjusted operating margin decreased, but improved excluding unfavorable currency. Tariffs reduced operating profit by 4%.

    Items below operating profit
    $0.13better than guidance
    Q1 FY26

    Better than guidance, including benefits from changes in interest rates and other income.

    Adjusted EPS
    $8.91+9% YoY
    Q1 FY26

    Incremental tariff costs were a gross headwind to EPS of 4%.

    Reported EPS
    $8.33vs $7.81 prior year
    Q1 FY26

    Reported EPS included specific adjustments.

    Days Sales Outstanding (DSO)
    35 days
    Q1 FY26

    DSO for the quarter.

    Inventory Turns (ITO)
    4.2x
    Q1 FY26

    Inventory turns for the quarter.

    R&D expense
    $51 million+1% LC YoY
    Q1 FY26

    R&D expense increased in local currency over the prior period.

    SG&A expense
    $258 million+1% LC YoY
    Q1 FY26

    SG&A increased in local currency, including sales and marketing investments offset by cost savings.

    Service revenue growth
    +7%
    Q1 FY26

    Strong service revenue growth, with 2% driven by acquisitions.

    Pricing
    3.5%
    Q1 FY26

    Price realization came in as expected in Q1.

    Pricing (Q2 FY26 expectation)
    2.5%
    Q2 FY26

    Expected pricing for Q2, stepping down due to lapping prior year's mid-year pricing actions.

    Pricing (H2 FY26 expectation)
    2%
    H2 FY26

    Holding normalized 2% pricing for the second half, with potential for upside.

    Pricing (Full-year FY26 expectation)
    2.5%
    FY26

    Full-year pricing expectation.

    China government grant
    $6 million
    Q1 FY26

    Grant from local government in Shanghai, consistent with the 'China for China' strategy. Funds will be excluded from cash flow statement.

    Semiconductor industry revenue contribution
    low single-digit
    Q1 FY26

    The ultra-pure water business within Process Analytics is doing extremely well, driven by semiconductor build-outs and data centers, but represents a small portion of total revenue.

    Industry KPIs

    6
    MetricValueDetails
    Revenue EPS guidanceFY26 LC sales growth ~4%; FY26 Adj EPS $46.30-$46.95 (+8-10% growth)
    China revenue exposure+4%%
    Pricing price realization3.5%%
    M a contribution synergies1.5%%
    Segment organic revenue growthflat%
    Reshoring US manufacturing tailwindearly innings

    Product announcements

    5
    ProductTypeDetails
    EasyMax advanced automated lab reactorlaunch
    InMotion PX One autosamplerlaunch
    Low retention pipettes (PFAS-free)launch
    X-ray solutions (expanded portfolio)expansion
    M50 R-Series metal detectorslaunch

    Deals & partnerships

    1
    AcquisitionsMultiple acquisitions contributing to sales growth

    Acquisitions are performing well, with teams focused on integration. The contribution to full-year sales guidance was increased from previous estimates.

    Risks & headwinds

    5
    Increased uncertainty in macroeconomic environmentQ1 FY26, continuing into Q2 FY26

    Customer delays in Q1; impacted Core Industrial sales (flat ex-acquisitions)

    Mitigation: Agility and strong execution of growth and margin expansion programs; confidence in H2 FY26 growth based on pipeline activity and improving global indicators.

    Middle East conflict and higher global energy costsQ1 FY26, ongoing

    Increased uncertainty in end markets; 4% gross headwind to operating profit and EPS in Q1; 90 bps headwind to gross margin in Q1; chemical sector softness in Europe

    Mitigation: Mitigation through cost savings initiatives and additional pricing actions; cautious approach to guidance given dynamic environment.

    Tariff headwindQ1 FY26, assumed to return to prior IEEPA rates mid-year

    90 basis points headwind to gross margin in Q1; 4% gross headwind to operating profit and EPS in Q1

    Mitigation: Guidance includes a temporary benefit from changes to U.S. import tariff rates in February; potential for tariff refunds from U.S. government (not included in guidance).

    Soft demand from academia and biotech customersQ1 FY26

    Negative growth in pipettes; Lab sales flat ex-acquisitions

    Mitigation: Expect conditions to gradually improve throughout 2026 for Lab; strong bioprocessing growth; new product launches (e.g., PFAS-free pipettes) to compete better.

    Lumpiness in Food Retail businessQ1 FY26, expected in Q2 FY26 for Americas

    Down double-digit in U.S. in Q1, offset by strong growth in Europe

    Mitigation: New innovation in the last few years is well-received; team is competing well despite inherent lumpiness.

    What to watch in Q2 FY26

    5

    Organic sales growth

    H2 FY26
    Current1% LC ex-acquisitions (Q1 FY26)
    TargetImproved organic growth, particularly in Lab and Core Industrial

    Why it matters

    Management expects a stronger second half driven by pipeline conversion and improving macro conditions, which is critical for meeting full-year targets.

    But we still feel very good about growth for the second half. I mean we'll talk a little bit more about that throughout the day. But I mean you kind of see a lot of positive indicators out there externally in terms of the PMIs. You see just global indicators looking positive. But when we look at our own pipeline, we also feel good about that as well.

    Q&A highlights

    6

    Why was the M&A contribution to sales guidance increased, implying a modest reduction in organic growth assumptions, and where is this organic softness concentrated (Lab vs. Industrial)?

    Acquisition performance is strong, leading to an increased contribution. The modest organic reduction reflects first-half uncertainty, with expectations for stronger second-half growth. Lab is expected to be low single-digit organic, Core Industrial low single-digit organic (with China strength offsetting Western softness), and Product Inspection low single-digit organic reflecting Q1 strength. Americas is expected to be flattish in Q2 due to retail lumpiness, Europe to step up, and China's full-year growth expectations were raised to mid-single digits.

    So of course, that implies maybe a modest reduction in the organic number. I think that largely reflects a little bit of this uncertainty in the first half of the year. We're taking still a cautious approach to the second quarter just given the environment. But we still feel very good about growth for the second half.

    asked by Michael Ryskin · answered by Shawn Vadala

    2 min read6 chapters

    Detailed Narrative

    01

    Innovation and Product Portfolio Expansion

    Mettler-Toledo continues to invest in innovation, launching new products across its segments. Recent introductions include the EasyMax advanced automated lab reactor for process development, the InMotion PX One autosampler for automated lab measurements, and PFAS-free low retention pipettes. In Industrial, the company expanded its X-ray solutions for mid-market coverage and introduced the M50 R-Series metal detector with 20% increased detection sensitivity, contributing to strong sales growth and market share gains in Product Inspection.

    02

    Strategic Focus on High-Growth Segments

    The company is actively targeting high-growth segments such as bioprocessing, new energy, and semiconductor. Bioprocessing continues to show strong growth, driven by demand for automation and digitalization solutions, including bioreactor sensors and integrated intelligent sensor management systems. The semiconductor industry, particularly the ultra-pure water business within Process Analytics, is also performing extremely well, albeit representing a low single-digit contribution to total revenue.

    03

    Geographic Performance and China Momentum

    Asia/Rest of World demonstrated good growth, with China growing 4% in Q1, primarily driven by the Industrial automation business and pharma investments related to Pharmacopoeia changes. This momentum led to an increased full-year growth expectation for China to mid-single digits. Other emerging markets like India and Southeast Asia also showed very good growth. Americas sales were flat excluding acquisitions, while Europe saw softer conditions, particularly in the chemical sector due to higher energy costs.

    04

    Customer Behavior and Second Half Outlook

    Management noted increased market uncertainty🌐 and customer delays in Q1, particularly in Western markets and the chemical sector, leading to a cautious approach for Q2 guidance. However, they expressed confidence in a stronger second half, citing improving global economic indicators, increased activity in their sales pipeline, and no observed order cancellations. The anticipated recovery is expected to be driven by industrial automation solutions and a gradual improvement in lab conditions.

    05

    Service Business Strength

    The service business continues to be a key differentiator and growth driver, with revenue increasing 7% (5% excluding acquisitions) in Q1. The company is actively pursuing a dedicated service growth initiative to increase the attach rate on its installed base and improve customer loyalty. While connect rates vary by product (e.g., high for Product Inspection due to critical uptime needs), programs are in place to enhance service coverage across the portfolio.

    06

    Tariff Dynamics and Cost Management

    Tariffs presented a 90 basis point headwind to gross margin and a 4% headwind to operating profit and EPS in Q1. The company's guidance includes a benefit from changes to U.S. import tariff rates in February, but assumes tariffs return to prior IEEPA levels mid-year. Management is focused on mitigating higher costs from inflation and geopolitical events through cost savings and pricing actions, with potential upside if mitigation efforts outperform cautious guidance assumptions.

    AI-generated summary of the company’s earnings call. Not investment advice.